Celldex Therapeutics, Inc. (CLDX): Price and Financial Metrics


Celldex Therapeutics, Inc. (CLDX)

Today's Latest Price: $15.38 USD

0.01 (0.07%)

Updated Oct 29 4:00pm

Add CLDX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

CLDX Stock Summary

  • The ratio of debt to operating expenses for Celldex Therapeutics Inc is higher than it is for about just 7.79% of US stocks.
  • CLDX's price/sales ratio is 136.77; that's higher than the P/S ratio of 97.8% of US stocks.
  • In terms of volatility of its share price, CLDX is more volatile than 97.54% of stocks we're observing.
  • Stocks that are quantitatively similar to CLDX, based on their financial statements, market capitalization, and price volatility, are MESO, KLIC, CBIO, ETTX, and LOGC.
  • Visit CLDX's SEC page to see the company's official filings. To visit the company's web site, go to www.celldex.com.

CLDX Stock Price Chart Interactive Chart >

Price chart for CLDX

CLDX Price/Volume Stats

Current price $15.38 52-week high $19.32
Prev. close $15.37 52-week low $1.50
Day low $15.00 Volume 233,800
Day high $15.60 Avg. volume 1,200,257
50-day MA $13.89 Dividend yield N/A
200-day MA $7.43 Market Cap 601.76M

Celldex Therapeutics, Inc. (CLDX) Company Bio


Celldex Therapeutics is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. The company was founded in 2004 and is based in Hampton, New Jersey.


CLDX Latest News Stream


Event/Time News Detail
Loading, please wait...

CLDX Latest Social Stream


Loading social stream, please wait...

View Full CLDX Social Stream

Latest CLDX News From Around the Web

Below are the latest news stories about Celldex Therapeutics Inc that investors may wish to consider to help them evaluate CLDX as an investment opportunity.

Why Celldex Has Been A Big Winner In 2020

Celldex Therapeutics (CLDX) is a development-stage pharmaceutical company. It was once a high-flyer, before its lead candidate failed a Phase 3 trial in 2015. More recently, before the CDX-0159 news was announced in June, it was selling at about $3.00 per share. On September 30, 2020, Celldex closed at $14.83...

William Meyers on Seeking Alpha | October 1, 2020

The Daily Biotech Pulse: Eton Snags Second FDA Nod For Month, Vaccine Updates from Moderna, CureVac

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc (NASDAQ: XLRN ) (announced Health Canada approval of luspatercept for RBC transfusion-dependent anemia associated with beta-thalassemia) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Adial Pharmaceuticals Inc (NASDAQ: ADIL )(announced EUA for antibody test for COVID-19) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Blueprint Medicines Corp (NASDAQ: BPMC ) Cardiff Oncology Inc (NASDAQ: CRDF ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) Fate Therapeutics Inc (NASDAQ: FA...

Benzinga | September 30, 2020

The Daily Biotech Pulse: FDA Nod For Pfizer, Sorrento's COVID-19 Antibody Animal Data, Orphazyme's Wall Street Debut

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 28) 10X Genomics Inc (NASDAQ: TXG ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Beigene Ltd (NASDAQ: BGNE ) Cardiff Oncology Inc (NASDAQ: CRDF ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Evogene Ltd (NASDAQ: EVGN ) Fate Therapeutics Inc (NASDAQ: FATE ) Guardant Health Inc (NASDAQ: GH ) InVitae Corp (NYSE: NVTA ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Kura Oncology Inc (NASDAQ: KURA ) Lantern Pharma Inc. (NASDAQ: LTRN ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Prelude Therapeutics Incorporated (NASDAQ: PRLD ) (listed Thursday) Seattle Genetics, Inc. (NASDAQ: SGEN ) Shockwave Medical Inc...

Benzinga | September 29, 2020

Celldex Therapeutics to Present at Upcoming Healthcare Conferences

HAMPTON, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that the Company will participate in Fireside…

GlobeNewswire | September 10, 2020

Tricida Suffers Setback, And Other News: The Good, Bad And Ugly Of Biopharma

Tricida suffers setback on Veverimer front Tricida Inc. (TCDA) reported that the FDA has given a Complete Response Letter to the company for its application pertaining to Veverimer. The New Drug Application for the drug candidate was being reviewed under the Accelerated Approval Program. Tricida is looking to request a...

Avisol Capital Partners on Seeking Alpha | August 26, 2020

Read More 'CLDX' Stories Here

CLDX Price Returns

1-mo 3.71%
3-mo 49.47%
6-mo 580.53%
1-year 586.61%
3-year -57.98%
5-year -91.50%
YTD 589.69%
2019 -25.67%
2018 -92.96%
2017 -19.77%
2016 -77.42%
2015 -14.08%

Continue Researching CLDX

Here are a few links from around the web to help you further your research on Celldex Therapeutics Inc's stock as an investment opportunity:

Celldex Therapeutics Inc (CLDX) Stock Price | Nasdaq
Celldex Therapeutics Inc (CLDX) Stock Quote, History and News - Yahoo Finance
Celldex Therapeutics Inc (CLDX) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7696 seconds.